Viking Therapeutics is trading at $27.32, down 4.27%, amid weakness in biotech shares. - The XBI is down 2.04%; no fresh company-specific announcement explaining the October 8 decline was identified. - Rising oil and Treasury yields amid Middle East tensions weigh on stocks, though major indexes are down less than 0.5%. - Financing-related dilution concerns have been reported as a factor in broader weakness, but do not establish a session-specific catalyst.